170 related articles for article (PubMed ID: 23444945)
21. Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection.
Beuschlein F; Weigel J; Saeger W; Kroiss M; Wild V; Daffara F; Libé R; Ardito A; Al Ghuzlan A; Quinkler M; Oßwald A; Ronchi CL; de Krijger R; Feelders RA; Waldmann J; Willenberg HS; Deutschbein T; Stell A; Reincke M; Papotti M; Baudin E; Tissier F; Haak HR; Loli P; Terzolo M; Allolio B; Müller HH; Fassnacht M
J Clin Endocrinol Metab; 2015 Mar; 100(3):841-9. PubMed ID: 25559399
[TBL] [Abstract][Full Text] [Related]
22. Adjuvant mitotane in adrenocortical carcinoma.
Dickstein G; Shechner C; Nativ O
N Engl J Med; 2007 Sep; 357(12):1257-8; author reply 1259. PubMed ID: 17891838
[No Abstract] [Full Text] [Related]
23. Survivin in adrenocortical tumors - pathophysiological implications and therapeutic potential.
Sbiera S; Kroiss M; Thamm T; Beyer M; Majidi F; Kuehner D; Wobser M; Becker JC; Adam P; Ronchi C; Allolio B; Fassnacht M
Horm Metab Res; 2013 Feb; 45(2):137-46. PubMed ID: 23143666
[TBL] [Abstract][Full Text] [Related]
24. Development of a pharmacokinetic model of mitotane: toward personalized dosing in adrenocortical carcinoma.
Kerkhofs TM; Derijks LJ; Ettaieb H; den Hartigh J; Neef K; Gelderblom H; Guchelaar HJ; Haak HR
Ther Drug Monit; 2015 Feb; 37(1):58-65. PubMed ID: 24887633
[TBL] [Abstract][Full Text] [Related]
25. Benefits of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A Systematic Review and Meta-Analysis.
Tang Y; Liu Z; Zou Z; Liang J; Lu Y; Zhu Y
Biomed Res Int; 2018; 2018():9362108. PubMed ID: 29967789
[TBL] [Abstract][Full Text] [Related]
26. Diagnosis, treatment and outcome of adrenocortical cancer.
Mihai R
Br J Surg; 2015 Mar; 102(4):291-306. PubMed ID: 25689291
[TBL] [Abstract][Full Text] [Related]
27. Adjuvant mitotane in adrenocortical carcinoma.
Machens A; Dralle H
N Engl J Med; 2007 Sep; 357(12):1258-9; author reply 1259. PubMed ID: 17891837
[No Abstract] [Full Text] [Related]
28. Risk assessment in 457 adrenal cortical carcinomas: how much does tumor size predict the likelihood of malignancy?
Sturgeon C; Shen WT; Clark OH; Duh QY; Kebebew E
J Am Coll Surg; 2006 Mar; 202(3):423-30. PubMed ID: 16500246
[TBL] [Abstract][Full Text] [Related]
29. Adrenocortical carcinomas: a 12-year clinicopathologic study of 15 cases.
Menon V; Krishnamurthy SV
Indian J Pathol Microbiol; 2006 Jan; 49(1):7-11. PubMed ID: 16625963
[TBL] [Abstract][Full Text] [Related]
30. Mitotane treatment for adrenocortical carcinoma: an overview.
De Francia S; Ardito A; Daffara F; Zaggia B; Germano A; Berruti A; Di Carlo F
Minerva Endocrinol; 2012 Mar; 37(1):9-23. PubMed ID: 22382612
[TBL] [Abstract][Full Text] [Related]
31. Adjuvant mitotane in adrenocortical carcinoma.
Lee JE
N Engl J Med; 2007 Sep; 357(12):1258; author reply 1259. PubMed ID: 17891836
[No Abstract] [Full Text] [Related]
32. Adjuvant mitotane therapy of adrenal cancer - use and controversy.
Schteingart DE
N Engl J Med; 2007 Jun; 356(23):2415-8. PubMed ID: 17554125
[No Abstract] [Full Text] [Related]
33. The impact of tumor stage on prognosis in children with adrenocortical carcinoma.
Tucci S; Martins AC; Suaid HJ; Cologna AJ; Reis RB
J Urol; 2005 Dec; 174(6):2338-42, discussion 2342. PubMed ID: 16280838
[TBL] [Abstract][Full Text] [Related]
34. [Surgical strategy in the treatment of adrenal cortex cancer. Expanded and repeated interventions].
Borrelli D; Bergamini C; Borrelli A; Reddavide S; Lassig R; Valeri A
Ann Ital Chir; 2003; 74(3):311-7. PubMed ID: 14677288
[TBL] [Abstract][Full Text] [Related]
35. [Normalisation of contralateral adrenal function after long-term mitotane therapy in a girl after surgical treatment of adrenocortical carcinoma].
Lecka A; Ginalska-Malinowska M
Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006; 12(3):234-6. PubMed ID: 17020662
[TBL] [Abstract][Full Text] [Related]
36. Adjuvant mitotane in adrenocortical carcinoma.
Bertherat J; Coste J; Bertagna X
N Engl J Med; 2007 Sep; 357(12):1256-7; author reply 1259. PubMed ID: 17881760
[No Abstract] [Full Text] [Related]
37. Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy.
Ronchi CL; Sbiera S; Kraus L; Wortmann S; Johanssen S; Adam P; Willenberg HS; Hahner S; Allolio B; Fassnacht M
Endocr Relat Cancer; 2009 Sep; 16(3):907-18. PubMed ID: 19240185
[TBL] [Abstract][Full Text] [Related]
38. Pregnancy in a patient with adrenal carcinoma treated with mitotane: a case report and review of literature.
Tripto-Shkolnik L; Blumenfeld Z; Bronshtein M; Salmon A; Jaffe A
J Clin Endocrinol Metab; 2013 Feb; 98(2):443-7. PubMed ID: 23275528
[TBL] [Abstract][Full Text] [Related]
39. Validation of the prognostic role of the "Helsinki Score" in 225 cases of adrenocortical carcinoma.
Duregon E; Cappellesso R; Maffeis V; Zaggia B; Ventura L; Berruti A; Terzolo M; Fassina A; Volante M; Papotti M
Hum Pathol; 2017 Apr; 62():1-7. PubMed ID: 27916625
[TBL] [Abstract][Full Text] [Related]
40. Assessment of serum-free cortisol levels in patients with adrenocortical carcinoma treated with mitotane: a pilot study.
Alexandraki KI; Kaltsas GA; le Roux CW; Fassnacht M; Ajodha S; Christ-Crain M; Akker SA; Drake WM; Edwards R; Allolio B; Grossman AB
Clin Endocrinol (Oxf); 2010 Mar; 72(3):305-11. PubMed ID: 19473175
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]